Sanzyme Biologics

Sanzyme Biologics is a biotechnology company that specializes in fermentation and is known for producing, marketing, and selling proprietary probiotic strains. The company's flagship strain, SNZ 1969 Bacillus Coagulans, is widely used in products such as Sporlac. Additionally, the company operates within the aquaculture and poultry divisions, with its aquaculture division, Kenko, directly catering to export-based aquaculture farmers in India, and the poultry division, Sanco, collaborating with established market players to develop probiotics for feed and feed additive companies. Founded in 1969 and headquartered in India, Sanzyme Biologics also serves as a sister company to Sanzyme Pvt Ltd. Currently, there is no available information regarding the last investment or the investors involved in the last investment round. As pioneers in probiotics, Sanzyme Biologics stands as a key player in the manufacturing, pharmaceutical, and retail industries. With its focus on proprietary probiotic strains and its niche within the larger biotechnology landscape, the company presents an intriguing opportunity for potential investors seeking a foothold in the burgeoning probiotics market.